IPP Bureau
Novo Nordisk completes acquisition of Akero Therapeutics
By IPP Bureau - December 10, 2025
Akero became a wholly owned subsidiary of Novo Nordisk
Croda strikes strategic deal with Amino to boost global supply of high-purity amino acids
By IPP Bureau - December 10, 2025
The agreement pairs Croda’s global footprint and “smart science” approach with Amino’s precision manufacturing capabilities
Lilly to invest $6 billion in Huntsville manufacturing hub
By IPP Bureau - December 10, 2025
The new site will produce next-generation synthetic medicine active pharmaceutical ingredients
Lilly moves forward with $3.56-per-share acquisition of Adverum
By IPP Bureau - December 10, 2025
Trelleborg launches Costa Rica facility to supercharge global medical device production
By IPP Bureau - December 10, 2025
The new site marks the company’s first operation in the region
Zydus launches affordable biosimilar 'Zyrifa' for cancer-related bone complications
By IPP Bureau - December 10, 2025
Zyrifa is indicated for patients with bone metastases stemming from a wide range of solid tumors
Fermenta Biotech to invest Rs. 110 crore for Dahej plant expansion
By IPP Bureau - December 10, 2025
This strategic investment aims to bolster the company's position as a global leader in Vitamin D3 manufacturing
Zydus and Formycon secure US and Canada partnership for Keytruda biosimilar
By IPP Bureau - December 10, 2025
Formycon AG will develop, register, manufacture and supply the product, while Zydus Lifesciences Global FZE, United Arab Emirates will be responsible for the commercialization of FYB206 in the defined territories
.jpg "Cipla launches Yurpeak (tirzepatide) for the treatment of obesity and type 2 diabetes in India")
Cipla launches Yurpeak (tirzepatide) for the treatment of obesity and type 2 diabetes in India
By IPP Bureau - December 10, 2025
Tirzepatide is the first and only dual agonist glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors
Dr Reddy's inks $370 million licensing deal to sell Immutep's cancer drug Eftilagimod Alfa
By IPP Bureau - December 09, 2025
Dr Reddy’s will pay Immutep US$ 20 million upfront and could deliver as much as US$ 349.5 million in regulatory and commercial milestones
Caplin Steriles gets FDA final approval for Acetaminophen Injection, infusion bags
By IPP Bureau - December 09, 2025
Acetaminophen Injection is indicated for the management of mild to moderate pain in adult and pediatric patients 2 years and older
Venus Remedies secures final Rs. 11 crore payment from Cipla for AMR drug
By IPP Bureau - December 09, 2025
The patented product, developed by Venus Medicine Research Centre (VMRC) for the treatment of multidrug-resistant (MDR) infections, was sold to Cipla in 2019
Roche’s Columvi combo doubles survival in hard-to-treat lymphoma
By IPP Bureau - December 09, 2025
Columvi combined with gemcitabine and oxaliplatin dramatically extends survival in people with relapsed or refractory diffuse large B-cell lymphoma
Thermo Fisher opens Bioprocess Design Center in Hyderabad
By IPP Bureau - December 09, 2025
Expands bioprocessing footprint across Asia
WuXi Biologics teams up with Qatar Free Zones Authority to launch first Middle East CRDMO Centre
By IPP Bureau - December 09, 2025
This collaboration sets the stage for WuXi Biologics’ first integrated CRDMO center in the region
